Charles Schwab Investment Management Inc. grew its position in Gyre Therapeutics, Inc. (NASDAQ:GYRE - Free Report) by 392.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 113,648 shares of the company's stock after purchasing an additional 90,557 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.12% of Gyre Therapeutics worth $1,425,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also modified their holdings of the company. Rhumbline Advisers bought a new stake in Gyre Therapeutics during the 2nd quarter valued at approximately $123,000. Renaissance Technologies LLC acquired a new position in shares of Gyre Therapeutics during the second quarter worth approximately $166,000. Bank of New York Mellon Corp bought a new stake in shares of Gyre Therapeutics in the second quarter valued at approximately $218,000. Finally, WINTON GROUP Ltd acquired a new stake in shares of Gyre Therapeutics in the second quarter worth $220,000. 23.99% of the stock is currently owned by institutional investors and hedge funds.
Gyre Therapeutics Trading Up 11.3 %
GYRE stock traded up $1.13 on Tuesday, reaching $11.12. 79,313 shares of the company were exchanged, compared to its average volume of 73,852. Gyre Therapeutics, Inc. has a 12 month low of $8.26 and a 12 month high of $30.40. The stock's fifty day moving average price is $12.97 and its 200 day moving average price is $12.60.
Gyre Therapeutics Profile
(
Free Report)
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
Read More
Before you consider Gyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.
While Gyre Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
